Nora M. Navone, MD, PhD

Peer-Reviewed Articles

1. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh N, Guerra L, Lee YC, Lin SC, Yu G, Santos E, Melancon MP, Troncoso P, Navone NM, Gallick GE, Efstathiou E, Subudhi SK, Lin SH, Logothetis CJ, Panaretakis T. Radium-223 Treatment Increases Immune Checkpoint Expression in Extracellular Vesicles from the Metastatic Prostate Cancer Bone Microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
2. Cascardo F, Anselmino N, Páez A, Labanca E, Sanchis P, Antico-Arciuch V, Navone NM, Gueron G, Vázquez E, Cotignola J. HO-1 Modulates Aerobic Glycolysis through LDH in Prostate Cancer Cells. Antioxidants (Basel) 10(6), 2021. e-Pub 2021. PMID: 34208670.
3. Ranasinghe W, Shapiro DD, Zhang M, Bathala T, Navone NM, Thompson TC, Broom B, Aparicio A, Tu SM, Tang C, Davis JW, Pisters L, Chapin BF. Optimizing the diagnosis and management of ductal prostate cancer. Nat Rev Urol 18(6):337-358, 2021. e-Pub 2021. PMID: 33824525.
4. Ranasinghe W, Shapiro DD, Hwang H, Wang X, Reichard CA, Elsheshtawi M, Achim MF, Bathala T, Tang C, Aparicio A, Tu SM, Navone NM, Thompson TC, Pisters L, Troncoso P, Davis JW, Chapin BF. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol 79(2):298-306, 2021. e-Pub 2020. PMID: 33279304.
5. Lage-Vickers S, Bizzotto J, Valacco MP, Sanchis P, Nemirovsky S, Labanca E, Scorticati C, Mazza O, Mitrofanova A, Navone NM, Vazquez E, Cotignola J, Gueron G. The expression of YWHAZ and NDRG1 predicts aggressive outcome in human prostate cancer. Commun Biol 4(1):103, 2021. e-Pub 2021. PMID: 33483585.
6. Sinha KM, Bagheri-Yarmand R, Lahiri S, Lu Y, Zhang M, Amra S, Rizvi Y, Wan X, Navone NM, Ozpolat B, Logothetis C, Gagel RF, Huard J. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene 38(25):5038-5049, 2019. e-Pub 2019. PMID: 30858546.
7. Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J. Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease. Sci Transl Med 11(494), 2019. PMID: 31142679.
8. Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene 38(14):2451-2463, 2019. e-Pub 2018. PMID: 30532030.
9. Paindelli C, Navone NM, Logothetis CJ, Friedl P, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials 197:296-304, 2019. e-Pub 2019. PMID: 30682644.
10. Piyarathna DWB, Balasubramanian A, Arnold JM, Lloyd SM, Karanam B, Castro P, Ittmann MM, Putluri N, Navone NM, Jones JA, Yu W, Sandulache VC, Sikora AG, Michailidis G, Sreekumar A. ERR1 and PGC1α associated mitochondrial alterations correlate with pan-cancer disparity in African Americans. J Clin Invest 129(6):2351-2356, 2019. e-Pub 2019. PMID: 30920960.
11. Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. Prostate 78(16):1262-1282, 2018. e-Pub 2018. PMID: 30073676.
12. Faria M, Shepherd P, Pan Y, Chatterjee SS, Navone NM, Gustafsson JÅ, Strom A. The estrogen receptor variants β2 and β5 induce stem cell characteristics and chemotherapy resistance in prostate cancer through activation of hypoxic signaling. Oncotarget 9(91):36273-36288, 2018. e-Pub 2018. PMID: 30555629.
13. Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urol Oncol 36(8):15-26, 2018. PMID: PMID: 29887238.
14. Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, Navone NM, De-Juan-Pardo EM, Logothetis CJ, Hutmacher DW, Friedl P. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med 10(452), 2018. PMID: 30068572.
15. Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM Troncoso P, DePinho RA, Wang YA. An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. Cancer Res 78(14):3823-3833, 2018. e-Pub 2018. PMID: 29769196.
16. Gueron G, Anselmino N, Chiarella P, Ortiz EG, Lage Vickers S, Paez AV, Giudice J, Contin MD, Leonardi D, Jaworski F, Manzano V, Strazza A, Montagna DR, Labanca E, Cotignola J, D Accorso N, Woloszynska-Read A, Navone NM, Meiss RP, Ruggiero R, Vazquez E. Game-Changing Restraint of Ros-Damaged Phenylalanine, Upon Tumor Metastasis. Cell Death Dis 9(2):140, 2018. e-Pub 2018. PMID: 29396431.
17. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone NM Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2017. PMID: 29138344.
18. Jaworski FM, Gentilini LD, Gueron G, Meiss RP, Ortiz EG, Berguer PM, Ahmed A, Navone NM, Rabinovich GA, Compagno D, Laderach DJ, Vazquez ES. In vivo hemin conditioning targets the vascular and immunological compartments and restrains prostate tumor development. Clin Cancer Res 23(17):5135-5148, 2017. e-Pub 2017. PMID: 28512172.
19. Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542(7642):484-488, 2017. e-Pub 2017. PMID: 28166537.
20. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone NM, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. PMID: 28228262.
21. Paez AV, Pallavicini C, Schuster F, Valacco MP, Giudice J, Ortiz EG, Anselmino N, Labanca E, Binaghi M, Salierno M, Martí MA, Cotignola JH, Woloszynska-Read A, Bruno L, Levi V, Navone NM, Vazquez ES. Gueron GHeme Oxygenase-1 in the Forefront of a Multi-Molecular Network That Governs Cell-Cell Contacts and Filopodia-Induced Zippering in Prostate Cancer. Cell Death Dis, 2016. PMID: 28032857.
22. Ferrara F, Staquicini DI, Driessen WH, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W. Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer. Proc Natl Acad Sci U S A. e-Pub 2016. PMID: 27791181.
23. Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM. BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. Mol Cancer Res 14(4):324-31, 2016. e-Pub 2016. PMID: 26792867.
24. Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas. Epigenetics 11(3):184-93, 2016. e-Pub 2016. PMID: 26890396.
25. Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials 77:164-72, 2016. e-Pub 2015. PMID: 26599623.
26. Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Neoplasia 18(1):1-9, 2016. PMID: 26806347.
27. Labanca E, De Luca P, Gueron G, Paez A, Moiola CP, Massillo C, Porretti J, Giudice J, Zalazar F, Navone NM, Vazquez E, De Siervi A. Association of HO-1 and BRCA1 is Critical for the Maintenance of Cellular Homeostasis in Prostate Cancer. Mol Cancer Res 13(11):1455-64, 2015. e-Pub 2015. PMID: 26227317.
28. Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget 6(33):34329-41, 2015. e-Pub 2015. PMID: 26455377.
29. Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W. Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study. Cancer 121(14):2411-21, 2015. e-Pub 2015. PMID: 25832466.
30. Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A 112(27):8403-8, 2015. e-Pub 2015. PMID: 26080435.
31. Liu J, You P, Chen G, Fu X, Zeng X, Wang C, Huang Y, An L, Wan X, Navone NM, Wu CL, McKeehan WL, Zhang Z, Zhong W, Wang F. Hyperactivated FRS2α-mediated signaling in prostate cancer cells promotes tumor angiogenesis and predicts poor clinical outcome of patients. Oncogene. e-Pub 2015. PMID: 26096936.
32. Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W. Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors. Proc Natl Acad Sci U S A 112(12):3776-81, 2015. e-Pub 2015. PMID: 25762070.
33. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 29(2):515, 2015. PMID: 25651464.
34. . Dovitinib reduces prostate cancer bone metastases. Cancer Discov 4(11):OF3, 2014. e-Pub 2014. PMID: 25367965.
35. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014.). Sci Transl Med 6(252):252ra122, 2014. PMID: 25186177.
36. Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC. Hydrogel-based 3d model of patient-derived prostate xenograft tumors suitable for drug screening. Mol Pharm 11(7):2040-50, 2014. e-Pub 2014. PMID: 24779589.
37. Gueron G, Giudice J, Valacco P, Paez A, Elguero B, Toscani M, Jaworski F, Leskow FC, Cotignola J, Marti M, Binaghi M, Navone NM, Vazquez E. Heme-oxygenase-1 implications in cell morphology and the adhesive behavior of prostate cancer cells. Oncotarget 5(12):4087-102, 2014. PMID: 24961479.
38. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone NM, Thompson TC. Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
39. Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone NM, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res 74(6):1651-60, 2014. e-Pub 2014. PMID: 24473064.
40. Corn PG, Wang F, McKeehan WL, Navone NM. Targeting Fibroblast Growth Factor Pathways in Prostate Cancer. Clin Cancer Res 19(21):5856-66, 2013. e-Pub 2013. PMID: 24052019.
41. Cotignola J, Leonardi DB, Shahabi A, Acuna AD, Stern MC, Navone NM, Scorticati C, DeSiervi A, Mazza O, Vazquez E. Glutathione-S-gtransferase (GST) polymorphisms are associated with relapse after radical prostatectomy. Prostate Cancer Prostatic Dis 16(1):28-34, 2013. e-Pub 2012. PMID: 23146971.
42. Ferrando M, Wan X, Meiss R, Yang J, De Siervi A, Navone NM, Vazquez E. Heme Oxygenase-1 (HO-1) Expression in Prostate Cancer Cells Modulataes the Oxidative Response in Bone Cells. PLoS One 8(11):e80315, 2013. e-Pub 2013. PMID: 24224047.
43. Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate 72(15):1638-47, 2012. e-Pub 2012. PMID: 22457212.
44. Elguero B, Gueron G, Giudice J, Toscani MA, De Luca P, Zalazar F, Coluccio-Leskow F, Meiss R, Navone NM, De Siervi A, Vazquez E. Unveiling the association of STAT3 and HO-1 in prostate cancer: Role beyond heme degradation. Neoplasia 14(11):1043-56, 2012. PMID: 23226098.
45. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 41(4):1495-503, 2012. e-Pub 2012. PMID: 22895552.
46. Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q. Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma. Leukemia 26(9):2114-23, 2012. e-Pub 2012. PMID: 22425892.
47. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Vascular patterning and permeability in prostate cancer models with differing osteogenic properties. NMR Biomed 25(6):843-51, 2012. e-Pub 2011. PMID: 22134886.
48. Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth. Bone 50(3):695-703, 2012. e-Pub 2011. PMID: 22173053.
49. Sircar K, Huang H, Hu L, Cogdell D, Dhillon J, Tzelepi V, Efstathiou E, Koumakpayi IH, Saad F, Luo D, Bismar TA, Aparicio A, Troncoso P, Navone NM, Zhang W. Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer. Am J Pathol 180(3):895-903, 2012. e-Pub 2012. PMID: 22245216.
50. Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res 18(3):666-77, 2012. e-Pub 2011. PMID: 22156612.
51. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM. Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726-36, 2012. PMID: 22298898.
52. Sircar K, Huang H, Hu L, Liu Y, Dhillon J, Cogdell D, Aprikian A, Efstathiou E, Navone NM, Troncoso P, Zhang W. Mitosis phase enrichment with identification of mitotic centromere-associated Kinesin as a therapeutic target in castration-resistant prostate cancer. PLoS One 7(2):e31259, 2012. e-Pub 2012. PMID: 22363599.
53. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone NM, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra121, 2011. PMID: 22133722.
54. Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone NM, De Siervi A, Vazquez E.. Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. e-Pub 2011. PMID: 21833623.
55. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 71(8):846-56, 2011. e-Pub 2010. PMID: 21456067.
56. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM. Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene fusion Positive Prostate Cancer. Cancer Cell 19(5):664-78, 2011. PMID: 21575865.
57. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res 17(8):2328-38, 2011. e-Pub 2011. PMID: 21343372.
58. Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol 42(1):11-7, 2011. e-Pub 2010. PMID: 21040948.
59. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 2011. PMID: 22194926.
60. Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU. Adipose tissue-derived stem cells promote prostate tumor growth. Prostate 70(15):1709-15, 2010. e-Pub 2010. PMID: 20564322.
61. Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J Pathol 221(1):68-76, 2010. e-Pub 2010. PMID: 20191612.
62. Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V. Quantification of mineralized bone response to prostate cancer by noninvasive in vivo μCT and non-destructive ex vivo μCT and DXA. PLoS One 5(3):e9854, 2010. e-Pub 2010. PMID: 20360964.
63. Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ. Prioritizing genes associated with prostate cancer development. BMC Cancer 10(1):599, 2010. e-Pub 2010. PMID: 21044312.
64. Gueron G, De Siervi A, Ferrando M, Salierno M, De Luca P, Elguero B, Meiss R, Navone NM, Vazquez ES. Critical role of endogenous heme oxygenase 1 as a tuner of the invasive potential of prostate cancer cells. Mol Cancer Res 7(11):1745-55, 2009. e-Pub 2009. PMID: 19903769.
65. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDA ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 2008. PMID: 18490922.
66. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 2008. PMID: 18618013.
67. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res 14(12):3729-36, 2008. PMID: 18559590.
68. Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene 27(5):596-603, 2008. PMID: 17700537.
69. Sacca P, Meiss R, Casas G. Mazza O, Calvo JC, Navone NM, Vazquez E. Nuclear translocation of heme oxygenase-1 is associated to prostate cancer. Br J Cancer 97(12):1683-89, 2007. e-Pub 2009. PMID: 18026199.
70. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 2007. PMID: 17634423.
71. Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res 67(14):6544-8, 2007. PMID: 17638862.
72. Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM. In vivo imaging of prostate cancer involving bone in a mouse model. Prostate 67(1):50-60, 2007. PMID: 17031813.
73. Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG. Inhibition of bone remodeling and prostate skeletal metastases by the vascular targeting agent VEGF121/rGel. Cancer Res 66(22):10919-28, 2006. PMID: 17108129.
74. Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH. Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3. J Steroid Biochem Mol Biol 97(1-2):203-11, 2005. e-Pub 2005. PMID: 16081281.
75. Fizazi K, Navone NM. [Preclinical models of prostate cancer]. Bull Cancer 92(2):129-41, 2005. PMID: 15749642.
76. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-2903, 2004. PMID: 15517894.
77. Navone NM, Olive M, Troncoso P. Isolation and culture of prostate cancer cell lines. Methods Mol Med 88:121-32, 2004. PMID: 14634223.
78. Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res 9(7):2587-97, 2003. PMID: 12855635.
79. Martinez LA, Yang J, Vazquez ES, Rodriguez-Vargas Mdel C, Olive M, Hsieh JT, Logothetis CJ, Navone NM. p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23(8):1289-96, 2002. PMID: 12151346.
80. Veenendaal LM, Jin H, Ran S, Cheung L, Navone NM, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99(12):7866-71, 2002. PMID: 12060733.
81. Vidanes GM, Paton V, Wallen E, Peehl DM, Navone NM, Brooks JD. Silencing of pi-class glutathione S-transferase in MDA PCa 2a and MDA PCa 2b cells. Prostate 51(4):225-30, 2002. PMID: 11987150.
82. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone NM, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem 277(5):12622-31, 2002. e-Pub 2002. PMID: 11812785.
83. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordoñez NG, Troncoso P, Navone NM. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 8(3):775-781, 2002. PMID: 11895908.
84. Plonowski A, Schally AV, Nagy A, Groot K, Krupa M, Navone NM, Logothetis C. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 176(1):57-63, 2002. PMID: 11790454.
85. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, Stephens LC, Troncoso P, Wu X, Logothetis CJ, Nicolaou KC, Navone NM. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48(4):319-26, 2001. PMID: 11710633.
86. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Jamal N, Hu M, Olive M, Martinez LA, Wood CG, Logothetis CJ, Karsenty G, Navone NM. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 61(14):5652-59, 2001. PMID: 11454720.
87. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141(7):2548-56, 2000. PMID: 10875257.
88. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6:703-706, 2000. PMID: 10835690.
89. Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer. Clin Cancer Res 6(3):1190-97, 2000. PMID: 10741751.
90. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162(6):2192-99, 1999. PMID: 10569618.
91. Navone NM, Labate ME, Troncoso P, Pisters LL, Conti CJ, von Eschenbach AC, Logothetis CJ. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J Urol 161:304-308, 1999. PMID: 10037428.
92. Ozen M, Navone NM, Multani AS, Troncoso P, Logothetis CJ, Chung LW, von Eschenbach AC, Pathak S. Structural alterations of chromosome 5 in twelve human prostate cancer cell lines. Cancer Genet Cytogenet 106(2):105-109, 1998. PMID: 9797773.
93. Pisters LL Troncoso P, Navone NM. Prolonged survival with metastatic prostate cancer to bone. J Urol 159:2100, 1998. PMID: 9598540.
94. Rajagopal S, Navone NM, Troncoso P, Fritsche HA, Chakrabarty S. Modulation of cellular proliferation and production of prostate-specific antigen and matrix adhesion molecules in human prostate carcinoma cells by polypeptide growth factors: comparative analyses of MDA PCa2a with established cell lines. Int J Oncol 12(3):589-595, 1998. PMID: 9472097.
95. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM, Johnston D, Pollack A, Pathak S, von Eschenbach AC, Logothetis CJ. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3(12):2493-500, 1997. PMID: 9815652.
96. Polo CF, Buzaleh AM, Vazquez ES, Afonso SG, Navone NM, Battle AM. Griseofulvin-induced hepatopathy due to abnormalities in heme pathway. Gen Pharm 29:207-210, 1997. PMID: 9251900.
97. McDonnell TJ, Navone NM, Troncoso P, Pisters LL, Conti C, von Eschenbach AC, Brisbay S, Logothetis CJ. Expression of Bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol 157:569-574, 1997. PMID: 8996359.
98. Polo CF, Afonso SG, Navone NM, Rossetti MV, Battle AM. Zinc aminolevulinic acid dehydratase reactivation index as a tool for diagnosis of lead exposure. Ecotox and Environ Safety 32:267-272, 1995. PMID: 8964254.
99. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, Conti CJ, Chung LW. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 45:470-475, 1995. PMID: 7879337.
100. Chen Y, Navone NM, Conti CJ. Expression of cyclin D1 in human prostate cancer cell lines. Urol Oncol 1:101-108, 1995.
101. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, von Eschenbach AC, Conti CJ. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85:1657-1669, 1993. PMID: 7692074.
102. Navone NM, Afonso SG, Polo CF, Batlle AM. Uroporphyrinogen decarboxylase from mouse mammary carcinoma and liver of normal and tumor-bearing mouse. Comp Biochem Physiol 102(1):87-92, 1992. PMID: 1526139.
103. Navone NM, Vazquez ES, Polo CF, Batlle AM. Rhodanese and ALA-S in mammary tumor and liver from normal and tumor-bearing mice. Comp Biochem Physiol 102B(1):83-5, 1992. PMID: 1526138.
104. Conti CJ, Bianchi AB, Navone NM, Ruggieri BA, Caamano J, Goodrow T, Klein-Szanto AJ. Tumor suppressor genes in squamous cell carcinoma. Prog Clin Biol Res 376:85-101, 1992. PMID: 1528931.
105. Navone NM, Bianchi AB, Angel JM, Conti CJ. A novel polymorphism near the mouse Int-2 locus. Mamm Genome 3:296-297, 1992. PMID: 1638089.
106. Bianchi AB, Navone NM, Conti CJ. Detection of loss of heterozygosity in formalin-fixed paraffin-embedded tumor specimens by the polymerase chain reaction. Am J Pathol 138:279-84, 1991. PMID: 1992758.
107. Navone NM, Buzaleh AM, Polo CF, Afonso SG, Vazquez ES, Batlle AM. The effect of griseofulvin on the heme pathway--II. An exhaustive analysis during short and long-term challenge. Gen Pharmacol 22:1179-83, 1991. PMID: 1810812.
108. Navone NM, Polo CF, Frisardi AL, Battle AM. Mouse mammary carcinoma porphobilinogenase and hydroxymethylbilane synthetase. Comp Biochem Physiol 98:67-71, 1991. PMID: 2060282.
109. Bianchi AB, Navone NM, Conti CJ. Overlapping loss of heterozygosity by mitotic recombination on mouse chromosome 7F1-ter in skin carcinogenesis. Proc Natl Acad Sci USA 88:7590-7594, 1991.
110. Afonso SG, Polo CF, Navone NM, Vazquez ES, Buzaleh AM, Schoua E, Battle AM. In vivo prevention and reversal by the antimitotic colchicine and other related compounds of some porphyrinogenic drug action on heme pathway. Gen Pharmacol 21:423-6, 1990. PMID: 2379798.
111. Navone NM, Polo CF, Dinger RM, Battle AM. Heme regulation in mouse mammary carcinoma and liver of tumor bearing mice I. Effect of allyl-isopropylacetamide and veronal on delta-aminolevulinate synthetase, cytochrome P-450 and cytochrome oxidase. Int J Biochem 22(9):1005-8, 1990. PMID: 2178097.
112. Navone NM, Polo CF, Frisardi AL, Andrade NE, Battle AM. Heme biosynthesis in human breast cancer. Mimetic "in vitro" studies and some heme enzymatic activity levels. Int J Biochem 22:1407-11, 1990. PMID: 2276414.
113. Navone NM, Polo CF, Frisardi AL, Battle AM. Mouse mammary carcinoma alpha-aminolevulinate dehydratase. Comp Biochem Physiol 96:729-31, 1990. PMID: 2225774.
114. Polo CF, Navone NM, Cirigliano A, Garro J, Rossetti MV, Wider EA. Un metodo para la medicion de la actividad de Uroporfirinogeno Decarboxilasa. Acta BioqClin Latinoamer XXIII:183-185, 1990.
115. Navone NM, Frisardi EL, Resnik A, Battle AM, Polo CF. Porphyrin biosynthesis in human breast cancer. Preliminary mimetic “in vitro” studies. . Med Sci Res 16:61-62, 1988.
116. Polo CF, Navone NM, Afonso SG, Buzaleh AM, Schoua E, Vazquez ES, Batlle A. Allyl-isopropyl-acetamide and glycerine reproduce in mice clinical and biochemical manifestations of acute intermittent porphyria. Med Sci Res 15:1335-6, 1988.
117. Polo CF, Navone NM, Afonso SG, Buzaleh AM, Schoua E, Battle AM. Planificacion de los estudios bioquimicos para un laboratorio de porfiria. . Acta Bioq Clin Latinoamer XXII 543:559, 1988.
118. Vazquez E, Afonso SG, Buzaleh AM, Navone NM, Polo CF, Schoua E, Battle AM. The effect of griseofulvin on the heme pathway. Studies on tissue explants cultures. Toxicology 46(1):73-82, 1987. PMID: 3660422.
119. Afonso SG, Buzaleh AM, Navone NM, Polo CF, Schoua E, Vazques E, Battle AM. Acerca de la fototoxicaidad de la griseofulvina. possibles mecanismos de accion empleando cultivos de explantes tisulares. Rev. Arg Dermatol 68:303-10, 1987.
120. Soto I, Navone NM, Rossetti MV, Vaquero N, Batlle A. Lepra y porfiria cutanea tarta. primer caso de coexistencia. Rev Arg Dermatol 68:107-13, 1987.
121. Vazquez E, Navone NM, Polo CF, Afonso SG, Buzaleh AM, Battle AM. Biosintesis de porfirinas en cultivo de explantes tisulares. condiciones optimas. Rev Arg Dermatol 68:121-29, 1987.
122. Parera VE, Afonso SG, Navone NM, Stella AM, Battle AM, Aguilar P, Mendez L, Castagno J, Gianantonio CA. Porfiria variegata en una nina de 4 anos. Rev Arg Dermat 67:129-31, 1986.
123. Vazquez E, Buzaleh AM, Navone NM, Polo CF, Schoua E, Afonso SG, Battle AM. Cultivo de explantes tisulares II: grado de lisis y su proteccion por el acido-amino -aminoolevulico. Ann Med Intern (Madrid) 3:258-62, 1986.

Invited Articles

1. Navone NM. P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells. Cell Cycle 9(15):2933-35, 2010. e-Pub 2010. PMID: 20703082.
2. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL. The current state of preclinical prostate cancer animal models. Prostate 68(6):629-39, 2008. PMID: 18213636.
3. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 14(6):1599-602, 2008. PMID: 18347159.
4. Logothetis C, Tu SM, Navone NM. Targeting prostate cancer bone metastases. Cancer 97(3 Suppl):785-8, 2003. PMID: 12548576.
5. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev 17(4):361-31, 1998. PMID: 10453280.

Abstracts

1. Labanca E, Yang J, Shepherd P, Wan X, Roberts JM, Starbuck MW, Navone NM. A specific pan-FGFR inhibitor has antitumor activity against prostate cancer patient derived xenografts, PDX, expressing high FGFR1. AACR Annual Meeting 2018, 2018.
2. Brasil da Costa FH, Navone NM, Farach-Carson MC, Carson DD. Heparan sulfate modifiers and signaling between tumor-associated macrophages and cancer-associated fibroblasts in a biomimetic hydrogel model of bone-metastatic prostate cancer. AACR Annual Meeting 2018, 2018.
3. Sablatura L, Bircsak KM, Farach-Carson MC, Navone NM, Shepherd P, Zarembinski T, Constantinou PE, Saleh A, Harrington DA. A 3D perfusable platform for high-throughput screening diverse racial/ethnic prostate cancer specimens. AACR Annual Meeting 2018, 2018.
4. Antico Arciuch VG, Cascardo F, Velazquez F, Vickers SL, Anselmino N, Labanca E, Cotignola J, Gueron G, Navone NM, Vazquez E. Heme oxygenase 1 drives the metabolic fate in prostate cancer. AACR Annual Meeting 2017, 2017.
5. Labanca E, Yang J, Shepherd P, Roberts J, Starbuck M, Broom B , Iyer M, Logothetis C, Chinnaiyan A, Navone NM. Expression of fibroblast growth factor receptor 1 isoforms and activation of different pathways in prostate cancer progression. AACR Annual Meeting 2017, 2017.
6. Roberts JM, Labanca E, Shepherd P, Yang J, Starbuck MW, Navone NM. The role of actvated beta-catenin/wnt signaling in the progression of castration resistance of prostate cancer in bone. AACR Annual Meeting 2017, 2017.
7. Bagheri-Yarmand R, Navone NM, Wan X, Logothetis C, Huard J, Sinha K. Oncogenic and osteolytic function of histone demethylase NO66 in castration resistant prostate cancer. AACR Annual Meeting 2016, 2016.
8. Labanca E, Wan X, Yang Y, Iyer M, Logothetis CJ, Chinnaiyan A, Navone NM. Alpha and beta isoforms of fibroblast growth factor receptor 1 in prostate cancer. AACR Annual Meeting 2016, 2016.
9. Geraldine G, Anselmino N, Chiarella P, Ortiz E, Paez A, Giudice J, Schuster F, Leonardi D, Jaworski F, Labanca E, Manzano V, Cotignola J, Meiss R, D´Accorso N, Navone NM, Ruggiero R, Vazquez E. School of Sciences- Univ. of Buenos Aires - IQUIBICEN- CONICET, Buenos Aires, Argentina; IMEX-CONICET - National Academy of Medicine, Buenos Aires, Argentina; Baylor College of Medicine, Houston, TX; MDAnderson Cancer Center, Houston, TX; School of Sciences- Univ. of Buenos Aires -CIHIDECAR-CONICET-UBA, Buenos Aires, Argentina; IMEX- CONICET, National Academy of Medicine, Buenos Aires, Argentina. Clinical implications for m-tyrosine, an isomer of p-tyrosine, for the treatment of aggressive prostate tumors. AACR Annual Meeting 2016, 2016.
10. Brasil FH, Ferrer V, Navone NM, Farach-Carson MC, Carson DD. Rice University, Houston, TX; University of Texas MD Anderson Cancer Center, Houston, TX. Heparan sulfate modifying enzymes deliver cancer, stromal and macrophage-produced heparin-binding growth factors in the prostate cancer microenvironment. AACR Annual Meeting 2016, 2016.
11. Paez AV, Pallavicini C, Schuster F, Giudice J, Valacco P, Labanca E, Anselmin N, Ortiz E, Binaghi M, Cotignola J, Marti M, Bruno L, Levi V, Navone NM, Vazquez E, Gueron G. IQUIBICEN-UBA/CONICET, Buenos Aires, Argentina; Department of Physics, FCEN, University of Buenos Aires, Buenos Aires, Argentina; Department of Cell Biology and Physiology. School of Medicine. University of North Carolina at Chapel Hill, Chapel Hill, NC; Department of Genitourinary Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX. Hitting the brakes on the migratory capacity of tumoral cells: Targeting key regulators of actin dynamics in prostate cancer. AACR Annual Meeting 2016, 2016.
12. Labanca E, Wan X, Yang J, Iyer M, Logothetis C, Chinnaiyan A, Navone NM. Fibroblast growth factor receptor 1 isoforms in prostate cancer bone metastases. AACR 2015Annual Conference, 2015.
13. Palanisamy N, Yang J, Wan X, Araujo JC, Efstathiou E, Pisters L, Bhalla R, Tomlins S, Kunju L, Chinnaiyan AM, Logothetis CJ, Troncoso P, Navone NM. Xenografts of Human Prostate Cancer - A Genetic profile Analysis. AACR 2013 Annual Conference, 2013.
14. Labanca E, Wan X, Yang J, Wang F, McKhaan W, Navone NM. FGF Signaling Axis Mediates the Interaction Between Prostate Cancer Cells and osteoblasts: Implications to PCa Bone Metastases. AACR 2013 Annual Conference, 2013.
15. Gueron G, Elguero B, Paez A, Giudice J, Toscani M, Jawoski F, Leonardi D, Coluccio-Leskow F, DeSiervi A, Navone NM, Vazquez E. Rearrangements of the E-cadherin/B-catenin-based adherens junctions caused by forced-expression of heme oxygenase 1(HO-1) in prostate cancer. AACR 2013 Annual Conference, 2013.
16. Gurski LA, Fong ELS, Milton RL, Xu X, Navone NM, Jia X, Harrington DA, Farach-Carson MC. Three-dimensional hyaluronan hydrogel culture systems facilitate study of the complex microenvironment of bone metastatic prostate cancer cells. AACR 2012 Annual Conference, 2012.
17. Gueron G, Ferrando M, Elguero B, Giudice J, Salles A, Labanca E, Jaworsky F, Colombo L, Meiss R, Navone NM, De Siervi A, Vazquez E. An auspicious target for state of the art anti-angiogenic therapeutic strategies and new insights in prostate carcinogenesis. AACR 2012 Annual Conference, 2012.
18. Kleb BN, Estecio M, Zhang J, Tzelepi V, Chung W, Maity SK, Logothetis C, Troncoso P, Navone NM, Jelinek J, Liang S, Issa JP, Aparicio A. The DNA methylome of castration-resistant prostate cancer. AACR 2012 Annual Conference, 2012.
19. Ferrando M, Elguero B, Meiss R, Tzelepi V, DeSiervi A, Navone NM, Vazquez E.. Heme oxygenase-1 is involved in prostate cane cells-bone interaction. AACR 2011 Annual Conference, 2011.
20. Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck M, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity S, Navone NM. Beta-catenin-TCF pathway and Castrate-Resistant Progression of Osteoblastic Bone Metastases. 2011 IMPaCT Conference, 2011.
21. Wan X, Yang J, Starbuck MW, Ravoori MK, Lu JF, Kundra V, Maity S, Wan F, Navone NM. Targeting fiboblast growth factor signaling in prostate cancer. 2010 Scientific Retreat and Rolanette and Berdon Lawrence Research Award Competition, Baylor College of Medicine, The Bone Disease Program of Texas, 2010.
22. Song Y-H, Navone NM, Corn P, Troncoso P, Alt E. The interaction between prostate cancer cells and tissue-resident stem cells influences tumor growth, metastasis and treatment strategies. V Foundation, 2010.
23. Wan X, Yang J, Starbuck MW, Ravoori MK, Lu JF, Kundra V, Maity S, Wang F, Navone NM. Targeting fibroblast growth factor signaling in prostate cancer. AACR 101st Annual Meeting, 2010.
24. Navone NM, McKeehan W, Wang F. Targeting FGF Signaling in Prostate Cancer Progression. 1st Annual Prostate SPORE Advisory Board Meeting, 2010.
25. Driessen WHP, Mandelin J, Cardo-Villa M, Kim J, Mathew P, Navone NM, Soghomonyan S, Flores LG, Alauddin MM, Gelovani JG, Pasqualini R, Arap W. Ligand-directed therapy and molecular imaging in a mouse model of androgen-independent osteogenic prostate cancer. AACR 101st Annual Meeting, 2010.
26. Park YY, Kim SB, Lim SM, Li ZG, Navone NM, Lee JS. Characterization of tumor-stromal interactions in microenvironment of prostate cancer bone metastasis. AACR 101st Annual Meeting, 2010.
27. Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Navone NM, Rosenblum MG. VEGF121/Gel inhibits prostate cancer-induced osteoblastogenesis by targeting osteoblasts and tumor neovasculature. AACR 101st Annual Meeting, 2010.
28. Gueron G, Ferrando M, Elguero B, Salles A, Meiss R, Colombo L, Curikno A, Facchinetti MM, Navone NM, deSiervi A, Vazquez E. Nuclear translocation of HO-1 in prostate cancer. Role beyond heme degradation. AACR 101st Annual Meeting, 2010.
29. Karlou MS, Yang J, Maity S, Navone NM, Lu JF, Wan X, Hoang A, Logothetis CJ, Efstathiou E. Preclinical model selection for the study of hedgehog signaling in androgen resistant/independent growth in prostate cancer from bedside to bench. 5th International Conference on Tumor Microenvironment: Progression, Therapy & Prevention - Poster Presentation, Versailles, France, 2009.
30. Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM. Osteoblastic and angiogenic reactions in prostate cancer bone metastasis models studied by macromolecular DCE-MRI and lower case Greek muCT. International Society for Magnetic Resonance in Medicine (ISMRM) 17th Scientific Meeting, Honolulu, Hawaii, 2009.
31. Li Z, Mathew P, Yang J, Liu J, Starbuck M, Zurita A, Sikes C, Multani A, Efstathiou E, Lopez A, Wang J, Fanning T, Prieto V, Kundra V, Troncoso P, Raymond A, Lin S, Vazquez E, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008.
32. De Luca P, Chamorro J, Grecco MR, Gueron G, Zalazar F, Gardner K, Navone NM. BRCA1 regulates GADD153-mediated apoptosis in prostate cancer cells. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008.
33. Gueron G, Ferrando M, De Luca P, Navone NM, de Siervi A, Vazquez E. Heme oxygenase 1 (HO-1): A novel protein in prostate cancer cell proliferation, migration and invasion. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, 2008.
34. Mohamedali KA, Poblenz AT, Kim S, yang J, Navone NM, Thorpe P, Darnay B, Rosenblum MG. Identification of the role of VEFG receptors in bone remodeling by the vascular targeting agent VEGF121/rGel. Proc Amer Assoc Cancer Res 47:9722, 2006.
35. Li ZG, Yingling JM, Logothetis C, Navone NM. TGB beta1 receptor kinase inhibitor inhibits prostate cancer growth in bone. Proc Amer Assoc Cancer Res 47:2922, 2006.
36. Li Z, Vakar-Lopez F, Ducy P, Logothetis C, Karsenty G, Lin, S-H, Navone NM. The role of DKK-1 in prostate cancer bone metastases. Proc Amer Assoc Cancer Res 46:2913, 2005.
37. Yang J, Karsenty G, Ducy P, Logothetis CJ, Navone NM. Targeting osteoblast signaling in the therapy of prostate cancer. . Proc Amer Assoc Cancer Res 46:2903, 2005.
38. Mohamedali KA, Poblenz AT, Sikes C, Luster T, Navone NM, Thrope P, Darnay B, Rosenblum MG. The vascular targeting agent VEGF 121/rGel inhibits bone remodeling and skeletal metastases through a unique mechanism. Proc Amer Assoc Cancer Res 46:4624, 2005.
39. Fizazi K, Sikes CR, Yang J, Kim J, Martinez LA, Logothetis CJ, Navone NM. High efficacy of docetaxel in preclinical models of advanced prostate cancer with and without androgen ablation and estramustine. . Proc Amer Assoc Cancer Res 44:810, 2003.
40. Kreimann EL, Yang J, Sikes CR, Olive M, Peleg S, Logothetis CJ, Karsenty G, Navone NM. The role of osteoblast IGF1-R signaling in matrix mineralization in a model of prostate cancer bone metastasis. Proc Amer Assoc Cancer Res 44:282, 2003.
41. Yang J, Kreimann EL, Sikes CR, Stephens CL, Lin S-H, Peleg S, Olive M, Logothetis CJ, Karsenty G, Navone NM. IGFBP-3 effect in prostate cancer cells and osteoblasts. Proc Amer Assoc Cancer Res 44 44:361, 2003.
42. Fizazi K, Martinez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM. P21 (WAF-1/CIP1) expression is associated with progression to androgen-independent prostate cancer. Proc Amer Assoc Cancer Res 43:1962, 2002.
43. Yang J, Fizazi K, Peleg S, Sikes CR, Raymond AK, Vazquez ES, Daliani D, Janus T, Logothetis CJ, Karsenty G, Navone NM. Endothelin-1 dependent and independent mechanisms concur in the increased bone mass of prostate cancer bone metastases. Proc Amer Assoc Cancer Res 43:1562, 2002.
44. Fizazi K, Yang J, Daliani D, Logothetis C, Peleg S, Navone NM. The effects of endothelin-1 and Abt-627, an endothelin-1 antagonist, in an in vitro model of bone metastases from prostate cancer. Proc Amer Assoc Can Res 42:1241, 2001.
45. Fizazi K, Yang J, Peleg S, Sikes CR, Raymond KA, Daliani D, Janus TJ, Logothetis CJ, Karsenty G, Navone NM. Multiple molecular events concur to induce osteoblastic bone metastasis in prostate cancer. Proc 6th World Congress on Advances in Oncology and 4th International Symposium on Molecular Medicine, 2001.
46. Martinez LA, Yang J, Fizazi K, Navone NM. p21 and p16 potentiate p53 mediated apoptotis in prostate cancer cells. . Proc Amer Assoc Can Res 42:900, 2001.
47. Navone NM, Yang J, Fizazi K, Sikes C, Vazquez E, Martinez LA. p53 regulates the response to growth factor deprivation and androgen withdrawal in prostate cancer cells in vitro and in vivo. . Proc Amer Assoc Can Res 42:1232, 2001.
48. Yang J, Fizazi K, Sikes CR, Martinez LA, Raymond K, Logothetis C, Peleg S, Navone NM. In vitro study of the biological basis of osteoblastic/osteoclastic bone metastases from prostate cancer. . Proc Amer Assoc Can Res 42:1217, 2001.
49. Martinez LA, Sikes CR, Hsieh JT, Navone NM. Role of p21 WAF1/CIP1 in prostate cancer drug resistance. Proc Amer Assoc Can Res 41:1598, 2000.
50. Navone NM, Yang J, Li M, Olive M, Logothetis CJ, Peleg S. Osteoblast-prostate cancer cells interaction attenuates the antiproliferative effect of vitamin D3. . Proc Amer Assoc Can Res 41:2338, 2000.

Book Chapters

1. Navone NM, and Labanca E. Modeling cancer metastasis. In: Patient-Derived Xenograft Models of Human Cancer. Humana Press, 93-114, 2017.
2. Navone NM, Olive M, Troncoso P. The isolation and culture of prostate cancer cell lines. In: Cancer Cell Culture-Methods and Protocols. Humana Press: Totowa, NJ, 121-132, 2004.
3. McDonnell, TJ, Bruckheimer EM, Gjerston BT, Honda T, Navone NM. The molecular regulation and therapeutic implications of cell death in prostate cancer. In: Cancer Chemotherapy and Apoptosis. Humana Press, 241-225, 1999.